SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...
Medexus Pharmaceuticals reported a strong performance in its Q3 FY2025 earnings call, with notable revenue growth and strategic advancements. The company highlighted a year-over-year increase in ...
The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...
Eton Pharmaceuticals said the Food and Drug Administration has extended by three months its review of the company's application seeking approval of its ET-400 liquid formulation of hydrocortisone.
X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its resources into recently approved rare disease drug mavorixafor.
Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...
State leaders are reviving talk of importing prescription drugs from Canada, even as US drugmakers and health-care attorneys ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback